¹ **The potential health impact and healthcare cost savings of** ² **different sodium reduction strategies in Canada**

3

4 Nadia Flexner^{1*}, Amanda C. Jones², Ben Amies-Cull³, Linda Cobiac⁴, Eduardo Nilson^{5,6}, Mary R. L'Abbe^{1*}

5 6

> ¹Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. ²Department of Public Health, University of Otago, Wellington, New Zealand. ³Nuffield Department of Primary Care Healthcare Sciences, University of Oxford, Oxford, United Kingdom. ⁴Griffith University, Queensland, Australia. ⁵Center for Epidemiological Research in Nutrition and Public Health, University of São Paulo, São Paulo, Brazil.

⁶Oswaldo Cruz Foundation (Fiocruz/Brasilia), Brasilia, Brazil.

*Corresponding authors: [mary.labbe@utoronto.ca;](mailto:mary.labbe@utoronto.ca) nadia.flexner@mail.utoronto.ca

7 **Keywords:** sodium reduction, health impact, cardiovascular disease, cost-utility analysis, multi-

- 8 state lifetable model, food policy.
- 9

¹⁰ **Abstract**

11 **Background**

- 12 High dietary sodium is the main dietary risk factor for non-communicable diseases due to its
- 13 impact on cardiovascular diseases, the leading cause of death globally. The Government of
- 14 Canada has taken measures to reduce average dietary sodium intakes, such as setting voluntary
- 15 sodium reduction targets for packaged foods and recently approving regulations mandating 'high
- 16 in' front-of-pack labeling (FOPL) symbols.

17 **Objectives**

To estimate the number of avoidable ischemic heart disease (IHD) and stroke incidence cases,

- and their associated healthcare cost and Quality-Adjusted Life Year (QALY) savings resulting
- from different sodium reduction strategies and recommendations in Canada.

Methods

 We used the PRIMEtime model, a proportional multi-state lifetable model. Outcomes were modeled over the lifetime of the population alive in 2019, at a 1.5% discount rate, and from the public healthcare system perspective. Nationally representative data were used as inputs for the model.

Results

Fully meeting Health Canada's sodium reduction targets was estimated to prevent 219,490 (95%

UI, 73,409–408,630) cases of IHD, and 164,435 (95% UI, 56,121–305,770) strokes. This led to a

- gain of 276,185 (95% UI, 85,414–552,616) QALYs, and healthcare costs savings of CAD\$
- 4,212(95% UI, 1,303–8,206) million over the lifetime of the 2019 cohort. Sodium reduction

intake through FOPL regulations has the potential to prevent between 35,930 (95% UI, 8,058–

- 80,528) and 124,744 (95% UI, 40,125–235,643) cases of IHD, and between 26,869 (95% UI,
- 5,235–61,621) and 93,129 (95% UI, 30,296–176,014) strokes. This results in QALY gains
- ranging from 45,492 (95% UI, 10,281–106,579) to 157,628 (95% UI, 46,701–320,622), and
- healthcare costs savings ranging from CAD\$ 695 (95% UI, 160–1,580) to CAD\$ 2,415 (95% UI,
- 722–4,746) million over the lifetime of the 2019 Canadian cohort. Greater health and healthcare
- costs gains were estimated if Canadians were to meet the population-level sodium intake

symbol would provide the most benefit from a public health standpoint.

1. Introduction

others(11).

when compared to previous sodium intake levels (i.e., 3,800 mg/day) using data from CCHS-

 In this study, we aimed to provide policymakers and stakeholders with evidence supporting policy options to reduce excess dietary sodium intakes in Canada. We estimated the number of avoidable ischemic heart disease and stroke incidence cases, and their associated healthcare cost, and Quality-Adjusted Life Year (QALY) savings resulting from 1) meeting sodium intake recommended levels, 2) meeting sodium reduction targets for packaged foods established by Health Canada, and 3) implementing 'high in' front-of-pack labeling regulations in Canada.

2. Materials and methods

 We conducted a cost-utility analysis using a public healthcare system perspective. The potential health and healthcare costs impact of reducing dietary sodium intake were modelled by comparing ten counterfactual scenarios (described below in section *'Counterfactual scenarios modeled'*) to a 'business as usual' or 'baseline' scenario. Outcomes were modeled over the lifetime of the Canadian population alive in 2019, and a 1.5% discount rate was applied to both health gains and healthcare costs, as recommended by the Canadian Agency for Drugs and Technologies in Health (CADTH)(22).

2.1PRIMEtime model: a proportional multi-state lifetable model

 The PRIMEtime model, an established and robust proportional multi-state lifetable model, was used in this study(23, 24). PRIMEtime is an epidemiological model tool, developed by researchers at the University of Oxford, that has been widely applied to a range of different diet and obesity policy scenarios in the UK and other countries(24-31). This model has been designed for policy scenario evaluation and can be utilized to assess future effects of policies in order to help policymakers set priorities for action. In a world of limited resources, governments are increasingly required to properly assess the cost-effectiveness of interventions to strategically allocate their resources. The PRIMEtime model is a tool for policy support and prioritization that under the same set of assumptions can help compare different policy options by assessing the cost-effectiveness of interventions.

 The PRIMEtime model is comprised of the following interconnected modules: a risk factor exposure module, a series of disease models, and a lifetable. Detailed methods of the model have been published elsewhere(24). Briefly, PRIMEtime uses epidemiological data collected mainly from meta-analyses of randomized control trials or prospective cohort studies to parameterize the relationships between risk factors and NCDs. This can be modeled as direct effects of risk factors or via their intermediate risk factors (i.e., blood pressure, BMI, or total cholesterol), where appropriate. The Canadian PRIMEtime Salt model includes the two main CVDs associated with high consumption of salt/sodium, IHD and stroke. These diseases are modeled in PRIMEtime in a three-state Markov model in which the population is either in a disease-free state, a diseased state, or dead. Then, the lifetable combines these simulated changes in population health and healthcare system as a result of changes in disease epidemiology.

 We adapted the PRIMEtime model to the Canadian context by collecting, processing, and analyzing Canadian-specific and nationally representative data (i.e., dietary sodium intakes, population demographics, disease epidemiology and healthcare costs). **Table 1** shows the data sources used as inputs for the PRIMEtime model in Canada. A closed cohort analyses was 139 performed, taking the Canadian adult population as a baseline $(\geq 19 \text{ y})$ over the lifetime of the cohort or until they reach 100y of age.

2.2Model input parameters

Population inputs

 Canadian population size and all-cause mortality data by 1-year age/sex groups were included in the model. Data was obtained from the publicly available Statistics Canada CANSIM tables for the year 2019 **(Table 1, Supplementary Table S1)**. All-cause mortality data was only available in 5-year age/sex groups; thus, further processing was required. Data was interpolated to 1-year using a temporal disaggregation method(32).

Disease epidemiology

Data on incidence, prevalence and disease-specific mortality were collected for ischemic heart

disease and stroke for the year 2019 **(Table 1)**. First, we prioritized alignment of WHO

International Statistical Classification of Diseases and Related Health Problems 10th Revision

(ICD-10) codes(33) between disease epidemiology and healthcare cost data (described below).

- Disease epidemiology data was only available in 5y age/sex groups up to age 90+ for all
- parameters; thus, further processing was required. Data was extrapolated to age 100+ using a
- polynomial trend line (**Supplementary Table S2**). Then, health data estimates were interpolated

- to 1y age/sex groups using a temporal disaggregation method to obtain smooth disaggregated counts, while maintaining the aggregated total(32).
- Case fatality rates were derived from cause-specific incidence, prevalence and mortality data, together with population size using a Bayesian approach, the *disbayes* optimization method built on the Stan software (*disbayes* package available in R)(32, 34). It was assumed that case fatality was constant for all ages below 35. The *disbayes* package estimates case fatality using a three- state transition process of disease free, disease, or death. The *disbayes'* approach and assumptions are consistent with the ones underpinning disease simulation in the PRIMEtime model (**Supplementary Table S1)**.
- Mean systolic blood pressure (SBP) estimates for the year 2019 were acquired. Data was
- available by sex (male, female) and age group (6-11 years, 12-19, 20-39, 40-59, 60-79) **(Table**
- **1)**. As SBP measurements were not available for individuals aged 80 years and older, we
- assumed the same values as those observed for 60-79 years age/sex groups for individuals in the 80+ years group.

Dietary sodium intake

 This study used data from the Canadian Community Health Survey (CCHS)-Nutrition 2015 to 172 estimate baseline and counterfactual dietary sodium intakes for Canadian adults $(\geq 19 \text{ y})$. CCHS- Nutrition 2015 is a nationally representative, cross-sectional health and nutrition survey that utilized 24-hour (24h) dietary recalls to collect data on food and beverage intake across the 10 Provinces of Canada (aged 1y or older)(35). We used both available days of 24h dietary recalls to estimate usual dietary sodium intakes for adults by Dietary Reference Intakes (DRI)(36)

- age/sex groups (i.e., males and females ages 19-30, 31-50, 51-70, 71+), methods that have been
- previously published by our research group(10, 20, 21).
- *Counterfactual scenarios modeled*
- *Meeting sodium intake recommended levels (Scenarios 1 and 2)*
- We modeled potential health and healthcare costs gains from meeting WHO sodium intake
- recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The
- proportion needed to meet these recommendations from the current sodium intakes (2,758
- mg/day) was calculated and applied to each DRI age/sex group to build our counterfactual
- scenarios¹⁰ **(Table 2, Supplementary Table S3)**.
- *Meeting sodium reduction targets established by Health Canada (Scenario 3)*
- Fully meeting Health Canada's voluntary sodium reduction targets for packaged foods was used as one of the counterfactual scenarios tested in this study. Our research group has previously published methods for this policy modeling approach(10, 37). Briefly, data from a Canadian branded packaged food composition database, the University of Toronto's Food Label Information and Price database (FLIP 2017), was linked to the Food and Ingredient Details (FID) file in the CCHS-Nutrition 24-hour recall to estimate baseline and counterfactual dietary sodium intakes. The counterfactual scenario was estimated after conducting a systematic 'reformulation' 194 of eligible packaged foods to meet Health Canada's sodium reduction targets¹⁰ (Table 2, **Supplementary Table S3)**.
- *Implementing 'high in' front-of-pack labeling regulations (Scenarios 4-10)*

 Based on recent FOPL evidence from observational and experimental studies(38-40), we estimated potential changes to dietary sodium intakes(20). These studies estimated changes in the content of nutrients of public health concern (i.e., saturated fats, sodium, and sugars) in food and beverage purchases when a 'high in' FOPL was in place. We assumed that changes observed in food and beverage purchases would carry over to dietary intakes, as evidence suggests that documented food purchases can serve as a reasonably precise estimate of overall diet quality(41). We modeled changes in overall food and beverage sodium content based on early evaluations of the Chilean Food Labeling and Marketing Law (-4.7%)(38) (*Scenario 4*), the criteria used by WHO to estimate FOPL cost-effectiveness as part of the *Technical briefing for Appendix 3 of the Global Action Plan for NCDs* (-6.4%)(40) (*Scenario 5*), and a FOPL systematic review and network meta-analysis (-7.8%)(39) (*Scenario 6*), **(Table 2, Supplementary Table S3)**. Furthermore, we constructed counterfactual scenarios using data from consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We first identified foods and beverages in FLIP 2017 similar to those reported in CCHS-Nutrition 2015 that would display at least one fewer 'high in' FOPL symbol for nutrients of concern, including sodium. Then, to estimate 'new' dietary intakes, we replaced nutritional values of identified foods for a random sample of 30%, 50%, and 70% of *CCHS-Nutrition* adult participants that consume at least one food that would display a 'high in' symbol (*Scenarios 7-9*). Additionally, to estimate the potential maximum effect of FOPL, we simulated changes for all adult participants (*Scenario 10*) **(Table 2, Supplementary Table S3)**. All FOPL counterfactual scenarios tested in this study are based on 'high in' FOPL evidence, which is the FOPL system recently approved in Canada. We have previously published methods

 for all FOPL policy scenarios(20, 21). For this study, we used potential impacts of implementing FOPL only for changes in sodium intakes.

Direct healthcare costs

 This study followed the perspective of the public healthcare system. The model estimated direct healthcare cost differences between the baseline and the modeled intervention. We used data from the 2010 Economic Burden of Illness in Canada (EBIC)(48), the most recent available and

comprehensive national disease-specific costs study. Direct healthcare costs in EBIC 2010 are

reported by diagnostic category disaggregated by age/sex groups.

 We followed previous published methods for the estimation of direct healthcare costs for each of the modeled diseases(49) (i.e., total and by prevalence case). We prioritized alignment of WHO ICD-10(33) codes between prevalence case data with EBIC 2010 categories, as well as disease definition as closely as possible with the Global Burden of Disease study (2019)(50). Therefore, we first identified the best fitting EBIC diagnostic category by matching ICD-10 codes for each disease under study. We used the EBIC 2010 online tool to produce costs for each EBIC category by sex (male, female) and age group (0-14 years, 15-34, 35-54, 55-64, 65-74, 75+)(51). Direct healthcare costs are comprised of attributable (drug, hospital care – day surgery, hospital care – inpatient, hospital care – other ambulatory care, hospital care – outpatient – clinic, hospital care – outpatient – emergency, and physician care) and unattributable direct costs (other institutions, other professionals, capital, public health, administration, and other health spending).

 EBIC diagnostic categories only provide disease-specific estimates for attributable direct costs, but also report total unattributable direct costs; thus, unattributable direct costs were estimated

 and added to cost estimates per disease. The proportion of each modeled disease's share to the total attributable direct cost was estimated for each age/sex group using a method developed by Krueger et al(52). Subsequently, this proportion was applied to the total unattributable direct costs to then include these estimates in the total direct healthcare costs for each disease. Costs per disease case were then calculated by dividing estimated direct healthcare costs for each age/sex group by prevalent cases in 2010, yielding the cost per case per year. A decision was made on using prevalent cases for each disease based on their clinical pattern of exerting costs; hence, these were treated as prevalent cases. Lastly, healthcare costs were inflated to 2019 Canadian Dollars (CAD), and inflation factor was estimated using the 'health care' sub-index from the Statistics Canada Consumer Price Index(53). Methods, sources, and direct healthcare costs estimations, by each modeled disease, are described in **Table 1** and **Supplementary Tables S4 and S5**.

2.3Sensitivity analysis

 Sensitivity analysis was conducted to examine the impact of uncertainty in the discount rate by applying 0% and 3% discount rate, as recommended by the CADTH(22). Additionally, we also used time horizons of 10 and 50 years.

2.4Statistical analysis

 The National Cancer Institute (NCI) method(54) was used to estimate Canadian adults' usual sodium intakes and distributions for all adults and by DRI age/sex group (baseline and counterfactual scenarios). The 1-part (amount only) model was used as zero consumption of sodium was <5%, as recommended by Davis et al(55), which also allowed us to stratify analysis

counterfactual scenario, by sex and each disease of interest. Uncertainty intervals (95% UI) were

produced using Monte Carlo simulation at 5000 iterations to allow the epidemiological

parameters in PRIMEtime to fluctuate randomly following the distributions considered in the

model(24).

3. Results

Meeting sodium intake recommendations

Fully meeting Health Canada's sodium reduction targets was estimated to reduce mean sodium

276 intakes to the national sodium intake recommendations $\left(\frac{2,300 \text{ mg/day}}{17\% \text{ reduction from}}\right)$

current levels). This reduction in sodium intake was estimated to prevent 219,490 (95% UI,

73,409 – 408,630) incident cases of IHD, and 164,435 (95% UI, 56,121 – 305,770) strokes.

Approximately, 63% of prevented IHD cases were estimated in males (137,188 [95% UI, 44,185

- 259,658]) and 37% in females (82,303 [95% UI, 29,224 148,972]), and 57% of prevented
- strokes were estimated in males (94,522 [95% UI, 31,032 179,060]) and 43% in females
- (69,913 [95% UI, 25,088 126,710]). These health gains result in an overall gain of 276,185

- Greater health and healthcare cost gains were estimated if Canadians were to meet WHO's
- population-level sodium intake recommendations (2,000 mg/day) and the Adequate Intake
- recommendation (1,500 mg/day) **(Tables 3 and 4, Figure 1 and 2)**.
- *Implementing 'high in' front-of-pack labeling regulations*
- Sodium intake reduction through the implementation of FOPL regulations, as suggested by early
- evaluations of the Chilean FOPL regulations, has the potential to prevent 57,023 (95% UI,
- 17,350 114,447) incident cases of IHD, and 41,794 (95% UI, 12,389 85,302) strokes.
- Approximately 64% of prevented IHD cases were estimated in males (36,323 [95% UI, 10,526 –
- 73,593]) and 36% in females (20,701 [95% UI, 6,824 40,854]), and 58% of prevented strokes
- were estimated in males (24,443 [95% UI, 7,028 50,943]) and 42% in females (17,351 [95%
- UI, 5,361 34,359]). These health gains result in an overall gain of 74,499 QALYs (95% UI,
- 21,108 160,246), with 63% attributed to males and 37% to females. This translates into CAD\$
- 1,149 million (95% UI, CAD\$ 329 CAD\$ 2,381) in healthcare cost savings (71% in males,
- 29% in females) over the lifetime of the 2019 Canadian cohort **(Tables 3 and 4, Figure 1 and**

2).

- Greater health and healthcare cost gains were projected based on the criteria used by WHO to
- estimate FOPL cost-effectiveness and results from a FOPL systematic review and network meta-

All sodium reduction strategies tested in this study were cost saving from the public healthcare

system perspective. Estimated benefits were greater for males than females in all scenarios

tested.

Sensitivity analysis

We examined the impact of uncertainty in the discount rate by applying discount rates of 3% and

0%. When a 3% discount rate was applied to both health and healthcare cost outcomes, a

- decrease of 44% and 39% were observed on average for QALYs and healthcare costs,
- respectively, in all scenarios. Conversely, when a 0% discount rate was applied, an increase of
- 96% and 78% were observed on average for QALYs and healthcare costs, respectively, in all
- scenarios (See **Supplementary Table S10**).

 Furthermore, using time horizons of 10 and 50 years, the model predicted that 7% and 76%, respectively, of estimated lifetime healthcare cost savings would occur within those time horizons. For QALYs gained, the model estimated that 4% and 67%, respectively, of estimated lifetime gains would occur within those same time horizons (See **Supplementary Table S11**).

4. Discussion

 This study estimated the potential impact of reducing sodium intake on the incidence of ischemic heart disease and stroke cases, savings in healthcare costs, and QALYs gains. Our results demonstrate that reducing sodium intakes through population-level strategies, such as implementing sodium reduction targets and 'high in' FOPL regulations, has the potential to improve health outcomes and reduce healthcare expenditures in Canada. This adds to current evidence, generated by simulation modeling studies, showing that sodium reduction strategies can potentially improve health outcomes and save costs to the health system, globally(29, 56-62) and in Canada(10, 19).

 To the best of our knowledge, this is the first study estimating the potential health (QALYs) and healthcare costs of current sodium reduction initiatives in Canada. We tested ten counterfactual scenarios aiming to reduce population sodium intake. These included achieving recommended sodium intakes levels (2,000 and 1,500 mg/day); meeting sodium reduction targets for packaged foods established by Health Canada (food reformulation, 2,300 mg/day); and estimated changes in sodium intake resulting from implementing the recently approved 'high in' FOPL regulations. As expected, our results showed the greatest health gains and healthcare cost savings from meeting population-level sodium intake recommendations of 2,000 mg/day (441,475 QALYs; CAD\$ 6,692 million in healthcare costs savings) and 1,500 mg/day (701,592 QALYs; CAD\$

 10,624 million in healthcare costs savings). Our study sheds light on how far Canadians are from achieving these maximum benefits with current sodium reduction policy initiatives.

 For instance, for the policy initiatives tested in this study (i.e., meeting sodium reduction targets and implementing 'high in' FOPL regulations), most health and healthcare costs gains were attributed to fully meeting Health Canada's sodium reduction targets (276,185 QALYs; CAD\$ 4,212 million in healthcare costs savings). Greater benefits were observed for males than females, in all scenarios tested, which could be attributed to differences in sodium consumption and CVD burden among Canadians males and females(9, 10, 63). Unfortunately, progress evaluations have shown that compliance with the voluntary sodium reduction targets has been limited, with only 14% of food categories meeting the targets by 2017(14), indicating that to meet targets by 2025(13) faster progress is needed. A robust government-led monitoring system and higher compliance from the food industry could contribute towards increasing sodium reduction progress in Canada. The consequences of not meeting established sodium reduction targets for processed foods represents an important missed opportunity to generate substantial health and healthcare costs gains in Canada.

 Canada could benefit from other countries experiences that have implemented mandatory sodium reduction targets. For instance, South Africa's legislation setting mandatory maximum sodium levels in foods has led to a decrease of 1.15 g/day in salt intake (~460 mg/day of sodium) in a four-year period (2015-2019). Interestingly, similar sodium reduction levels were estimated for our scenario of fully meeting sodium reduction targets(64), which indicates the feasibility of this strategy. This also highlights the importance of changing the voluntary nature of sodium reduction targets in Canada to mandatory sodium reduction targets. More recently, the WHO released the *WHO global sodium benchmarks for different food categories*(65). This set of

 sodium reduction targets includes 18 main food categories and 97 food subcategories. Greater benefits would be expected from meeting these targets in Canada, given that for several common food categories WHO targets are more stringent than Health Canada's sodium reduction targets. In Australia, it has been estimated that meeting WHO benchmarks, as opposed to meeting Australian sodium reduction targets, could prevent or delay nearly three and a half times as many diet related NCD deaths(62).

 The potential impact of FOPL regulations was estimated through two pathways. The first was based on recent FOPL evidence from observational and experimental studies(38-40) that estimated changes in the content of nutrients of public health concern, including sodium, in food and beverage purchases when a 'high in' FOPL was in place. Among these scenarios is one based on early evaluations of the Chilean FOPL (S4), which most likely captured consumer behavior change and initial industry-driven food reformulation. The health and healthcare cost gains estimated from this scenario represent approximately 27% of the gains estimated from meeting Health Canada's sodium reduction targets. The second pathway was based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47), which would only capture consumer behavior change. The estimated benefits from these scenarios range from 16% to 57% of the benefits estimated from meeting Health Canada's sodium reduction targets.

 The differences in FOPL scenarios tested are reflected in our estimates. We observed greater benefits from changes observed in food and beverage purchases in the presence of FOPL (S4-6) than from food substitution as a response of FOPL (S7-9). It is worth noting that our study focused solely on benefits from reducing sodium intake as a result of implementing FOPL in Canada. Therefore, it is expected that implementation of FOPL will result in greater health and

healthcare cost benefits, as it also targets other nutrients-of-concern (i.e., sugars and saturated

- fats) not accounted for in our estimates. For instance, a recent study from our research group
- estimated that 15% of diet related NCD deaths that could be averted or delayed due to
- implementation of FOPL in Canada were attributed to sodium(21).

A previous Canadian modeling study estimated potential heath and healthcare cost benefits, over

397 a 50-year time horizon, from reducing sodium intake levels by 1,500 mg/day(19). They

estimated benefits of 1,021,458 QALYs and CAD\$16,805 million in healthcare cost savings(19).

399 In comparison, the largest reduction we tested was a reduction in sodium intake of $1,258$ mg/day

to achieve the AI recommendations (1,500 mg/day). Under this scenario we projected benefits of

471,748 QALYs and CAD\$ 8,083 million in healthcare cost savings over a 50-year time horizon.

Differences likely stem from variations in the magnitude of the tested sodium reduction intake

(reductions of 1500 mg/day vs. 1,258 mg/day), differences in methodology used to estimate

healthcare costs, improved management of SBP in Canada, and slight reductions observed in the

burden of CVDs in Canada. In the US a sodium reduction of 1,200 mg/day has been predicted to

gain between 194,000 and 392,000 QALYs and save between \$10,000 to \$24,000 million in

healthcare costs(66).

 This study has limitations and strengths that need to be considered in the interpretation of our results. First, scenario modeling is an analytical technique; hence, results are as appropriate and generalizable as the data, assumptions and constraints that are applied to the mathematical model(67). To mitigate this, we used Canadian–specific and nationally representative data as inputs for the model. Additionally, our counterfactual sodium reduction intervention scenarios are based on Canadian sodium reduction targets and the most recent available evidence on the impact of FOPL regulations. We followed the perspective of the public healthcare system; hence,

 the costs of implementing the sodium reduction interventions were not considered. Although population-wide sodium reduction interventions in Canada were estimated to cost CAD\$2.02 per person annually (Canadian population in 2019: 38 million approximately), these costs would be minimal in comparison with savings in healthcare costs(19, 68). These costs included government led industry agreements to reduce sodium in packaged foods, government monitoring of industry compliance, and public health campaigns(19, 68). We also did not consider societal gains in our modeling, such as productivity gains from preventing premature deaths or disease burden.

 Furthermore, we focused on the potential health effects of reducing sodium intake, specifically health effects from IHD and stroke, the leading causes of death globally. However, recent studies have estimated potential effects of reducing sodium on other diseases such as chronic kidney disease and stomach cancer(58, 59, 69, 70). Therefore, our estimations of the potential benefits of reducing population-level sodium intake are conservative, considering that reducing sodium intake could also have positive effects on other diseases. Lastly, this study used data for the entire Canadian population without considering equity aspects. Future research can expand our work by examining the differential impacts of reducing sodium intake among diverse subgroups.

This study also has strengths to consider. Dietary sodium intake data was estimated using data

from a nationally representative sample of the Canadian population (CCHS-Nutrition 2015).

Surveys of this kind are usually prone to biases related to misreporting due to recall bias.

Nevertheless, CCHS-Nutrition 2015 used the Automated Multiple Pass Method to reduce the

impact of such reporting errors. We used the NCI method to estimate usual sodium intakes and

adjusted for age, sex, dietary misreporting status, weekend/weekday, and sequence of dietary

recall. For modeling we used the PRIMEtime model, a robust, validated and widely used

 proportional multi-state lifetable model(23, 24). Strengths and limitations of the model have been previously published(24). We also conducted sensitivity analysis to examine the impact of uncertainty in the discount rate by applying 0% and 3% discount rates, as has been recommended(22). As expected, variations in discount rates, both higher and lower than our main analysis (1.5% discount rate), had a significant impact on health and healthcare cost outcomes.

 Our findings provide evidence for policymakers and stakeholders of the potential benefits of reducing sodium intake through strategies widely discussed in Canada that target packaged foods. This is especially relevant because packaged foods are the main source of sodium intake for Canadians(9). Multicomponent strategies have proven to be more effective and are necessary for reaching the national and global sodium recommendations(11, 71). Therefore, in addition to moving from voluntary to mandatory sodium reduction targets for packaged foods and implementing 'high in' FOPL regulations, other initiatives should be considered for Canadians to meet population-level sodium intake recommendations (2,000 and 1,500 mg/day). These could include setting sodium reduction targets for restaurant foods, restricting marketing of foods 'high in' sodium, enabling healthy food environments in public settings by providing lower sodium options, regulating the digital food environment to require nutritional information, encouraging the use of low-sodium, potassium-enriched salt, and adopting approaches such as social marketing to develop behavior change communication and mass media campaigns(11, 72, 73). A combination of strategies, as has been recommended by the WHO's *SHAKE Technical Package for Salt Reduction*(11), would be of most benefit from a public health standpoint.

5. Conclusions

subgroups in Canada.

Conflict of interest

- The authors declare that the research was conducted in the absence of any commercial or
- financial relationships that could be construed as a potential conflict of interest.

Authors' contributions

- NF, AJ, and MRL conceptualized the study design; NF, AJ, BAC, LC, EN and MRL interpreted
- the findings; NF conducted the study, wrote the original draft, and performed the statistical
- analysis. All authors critically reviewed and approved the final manuscript.

Funding

- This research was funded by Canadian Institutes of Health Research (CIHR) operating grants
- (PJT-165858; SA2-152805; Healthy Cities Training Award). [https://cihr-irsc.gc.ca/e/193.html.](https://cihr-irsc.gc.ca/e/193.html)
- The funders had no role in study design, data collection and analysis, decision to publish, or
- preparation of the manuscript.

Acknowledgments

 The authors would like to thank Professor Peter Scarborough, University of Oxford, for allowing us to use the PRIMEtime model and discussing its application; as well as current and past L'Abbe lab members who worked on various aspects of the FLIP database, especially Anthea Christoforou who worked and published data on the sodium reformulation scenario used in this manuscript. Furthermore, the authors would like to acknowledge the assistance of Arantxa Bonifaz Rosas with the collection of Canadian healthcare cost data.

Data Availability Statement

- Analytic code (R) can be made available to researchers upon request to the author. *Canadian*
- *Community Health Survey-Nutrition 2015 Public Use Microdata File (PUMF)* data is publicly
- and freely available without restriction at Statistics Canada,
- https://www150.statcan.gc.ca/n1/en/catalogue/82M0024X
- Canadian population demographics, healthcare costs and epidemiology data associated with
- ischemic heart disease and stroke were obtained from publicly available sources also detailed
- in the main manuscript.
- <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501>
- <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310070901>
- <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310014701>
- <https://health-infobase.canada.ca/ccdss/data-tool/>
- <https://cost-illness.canada.ca/custom-personnalise/national.php>

505 SBP, systolic blood pressure.

506 **Table 2.** Sodium reduction counterfactual scenarios

507

508 *These values are overall intervention effect. Intervention effect by DRI age/sex group, as imputed in the PRIMEtime model, are detailed in Supplementary Table

509 S3. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). We considered the potential impacts of FOPL implementation solely
510 for changes in sodium intakes. FOPL, front-of-pack label

510 for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; mg, milligram; CCHS, Canadian Community Health Survey.

Community Health Survey.

512 **Figure 1.** Estimated QALY gained over the lifetime of the 2019 cohort, by sex and sodium reduction strategy

513
514

514 The potential QALYs gained were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual scenario have
515 been published elsewhere(10, 20, 21). Sodium intake goal

515 been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on WHO sodium intake recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The sodium target scenario was based on ful

516 recommendations of 1,500 mg/day. The sodium target scenario was based on fully meeting Health Canada's voluntary sodium reduction targets for packaged
517 foods. The FOPL-changes in F&B purchase scenarios were based on

517 foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–
518 food substitution scenarios were based on consumer research reporti

food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer

519 (high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack
520 labeling: WHO. World Health Organization: AI. Adequate Intake: OAL

labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

- 521 **Figure 2.** Estimated healthcare cost savings (CAD\$ million) over the lifetime of the 2019 cohort, by sex and sodium reduction
- 522 strategy
- 523

524
525

525 The potential healthcare cost savings were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual 526 scenario have been published elsewhere(10, 20, 21). Sodium i

- 526 scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day and the WHO
527 sodium intake recommendations of 2.000 mg/day. The sodium target sce
- 527 sodium intake recommendations of 2,000 mg/day. The sodium target scenario was based on fully meeting Health Canada's voluntary sodium reduction targets
528 for packaged foods. The FOPL-changes in F&B purchase scenarios
- 528 for packaged foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40).
- 529 The FOPL–food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products 530 with fewer 'high in' FOPL symbols(42-47). We considered the
- 530 with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-
531 pack labeling; WHO, World Health Organization; AI, Adequate pack labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

532 **Table 3.** Prevented disease incident cases over the lifetime of the cohort, by sex and sodium

533 reduction strategy

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.02.23297997;](https://doi.org/10.1101/2023.11.02.23297997) this version posted November 3, 2023. The copyright holder for this preprint

- 535 The potential health impacts were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full 536 diations details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium i
- 536 details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios 537 were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations o
- were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations of
- 538 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health Canada's voluntary sodium
- 539 reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios (S4-6) were based on recent
540 FOPL evidence from observational and experimental studies (38-40). The FOPL–food substitution scenarios (
- 540 FOPL evidence from observational and experimental studies(38-40). The FOPL–food substitution scenarios (S7-10)
- 541 were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols (42-47). We considered the potential impacts of FOPL implement
- 542 products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation
543 olely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, ischemic heart disease; WHO, Wor
- 543 solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, ischemic heart disease; WHO, World
544 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Surve
- 544 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey.

545 **Table 4.** Estimated health gains and healthcare cost savings over the lifetime of the cohort, by

546 sex and sodium reduction strategy

Counterfactual scenarios		QALY gains	$\%$	Healthcare cost savings	$\%$
				(CAD\$ million)	
Meeting sodium intake recommendations	S1: Meeting AI sodium intake recommendations				
	$(1,500 \text{ mg/day})$	$701,592$ (225,679 – 1,393,230)	100%	$10,624$ $(3,356 - 20,665)$	100%
	Males (95% UI)	$425,297$ (126,968 - 860,372)	61%	$7,295(2,183 - 14,410)$	69%
	Females (95% UI)	$276,295(98,711-532,858)$	39%	$3,329$ $(1,173 - 6,255)$	31%
	S2: Meeting WHO sodium intake recommendations				
	$(2,000 \text{ mg/day})$	$441,475$ $(135,508 - 891,597)$	100%	$6,692$ (2,092 - 13,017)	100%
	Males (95% UI)	$269,816(77,889 - 555,809)$	61%	$4,626$ (1,383 – 9,108)	69%
	Females (95% UI)	$171,659$ $(57,619 - 335,788)$	39%	$2,067(708-3,909)$	31%
	S3: Meeting sodium reduction targets for packaged				
	foods $(2,300 \text{ mg/day})$	$276,185(85,414-552,616)$	100%	$4,212$ $(1,303 - 8,206)$	100%
	Males (95% UI)	$169,889$ $(50,166 - 344,868)$	62%	$2,926(868-5,769)$	69%
	Females (95% UI)	$106,296(35,248-207,748)$	38%	$1,286(435 - 2,437)$	31%
- changes in food and beverage purchases FOPL	S4: Changes in food & beverage purchases				
	(Chilean experience)	$74,499$ $(21,108 - 160,246)$	100%	$1,149$ (329 - 2,381)	100%
	Males (95% UI)	$46,889$ $(12,607 - 102,243)$	63%	$814(220 - 1,708)$	71%
	Females (95% UI)	$27,609(8,501-58,003)$	37%	$336(109-673)$	29%
	S5: Based on WHO criteria to estimate cost-				
	effectiveness of FOPL policies	$99,867$ (29,314 - 210,195)	100%	$1,535(455 - 3,119)$	100%
	Males (95% UI)	$62,782$ (17,670 – 134,336)	63%	$1,085(308-2,231)$	71%
	Females (95% UI)	$37,084$ $(11,644 - 75,859)$	37%	$449(147-888)$	29%
	S6: Based on a FOPL systematic review and				
	network meta-analysis	$121,817$ (37,065 - 252,387)	100%	$1,876$ (573 - 3,802)	100%
	Males (95% UI)	$76,734$ (22,375 - 161,718)	63% 37%	$1,329(391 - 2,725)$ $548(181 - 1,077)$	71%
	Females (95% UI)	$45,083$ $(14,690 - 90,669)$			29%
titution FOPL - food subs	S7: Based on food substitution for 30% of CCHS- Nutrition 2015 adult participants	$45,492$ $(10,281 - 106,579)$	100%	$695(160-1,580)$	100%
	Males (95% UI)	$28,620(6,375-68,250)$	63%	492 $(110-1,123)$	71%
	Females (95% UI)	$16,872$ (3,906 - 38,329)	37%	$204(50-457)$	29%
	S8: Based on food substitution for 50% of CCHS- Nutrition 2015 adult participants	$80,321$ (23,373 - 169,543)	100%	$1,231$ $(367 - 2,549)$	100%
	Males $(95\% \text{ UI})$	$50,867$ $(14,373 - 108,277)$	63%	$875(254 - 1,835)$	71%
	Females (95% UI)	$29,454(9,001-61,265)$	37%	$356(113 - 714)$	29%
	S9: Based on food substitution for 70% of CCHS-				
	Nutrition 2015 adult participants	$110,063$ $(34,011 - 228,868)$	100%	$1,688(512-3,427)$	100%
	Males (95% UI)	$69,860$ $(20,880 - 147,630)$	63%	$1,202(351 - 2,468)$	71%
	Females (95% UI)	$40,203$ $(13,131 - 81,239)$	37%	$486(161-959)$	29%
	S10: Based on food substitution for all CCHS-				
	Nutrition 2015 adult participants	$157,628$ (46,701 - 320,622)	100%	$2,415(722 - 4,746)$	100%
	Males (95% UI)	$98,309$ $(27,375 - 203,349)$	62%	$1,696(482 - 3,376)$	70%
	Females (95% UI)	$59,318$ (19,326 - 117,273)	38%	$719(239 - 1,370)$	30%

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.02.23297997;](https://doi.org/10.1101/2023.11.02.23297997) this version posted November 3, 2023. The copyright holder for this preprint

- 547 The potential health gains and healthcare cost savings were estimated using the PRIMEtime model(24), with inputs
548 described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10,
- 548 described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium in take spall scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium
- 549 intake goal scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake
550 recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health
- recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health
- 551 Canada's voluntary sodium reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios
552 (S4-6) were based on recent FOPL evidence from observational and experimental studies (38-40). The FOPL–foo
- 552 (S4-6) were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–food
- 553 substitution scenarios (S7-10) were based on consumer research reporting the proportion of consumers that choose
554 or were willing to choose products with fewer 'high in' FOPL symbols (42-47). We considered the poten
- 554 or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts
555 of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, WHO,
- 555 of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, WHO, World
- 556 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey;
557 QALY, Quality-Adjusted Life Year; CAD\$, Canadian dollars.
- 557 QALY, Quality-Adjusted Life Year; CAD\$, Canadian dollars.

References

 1. Institute for Health Metrics and Evaluation (IHME). GBD Compare Seattle, WA: IHME, University of Washington, 2019.2019 [Available from: [http://vizhub.healthdata.org/gbd-](http://vizhub.healthdata.org/gbd-compare) [compare.](http://vizhub.healthdata.org/gbd-compare) 2. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global sodium consumption and death from cardiovascular causes. New England Journal of Medicine. 2014;371(7):624-34. 3. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018;71(19):e127- e248. 4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American College of Cardiology. 2020;76(25):2982-3021. 5. World Health Organization. Noncommunicable diseases country profiles 2018 2018 [Available from: [https://apps.who.int/iris/handle/10665/274512.](https://apps.who.int/iris/handle/10665/274512) 6. World Health Organization. Tackling NCDs: 'best buys' and other recommended interventions for the prevention and control of noncommunicable diseases 2017 [Available from: [https://apps.who.int/iris/handle/10665/259232.](https://apps.who.int/iris/handle/10665/259232) 7. World Health Organization. Saving lives, spending less: a strategic response to noncommunicable diseases Geneva, Switzerland.2018 [Available from: [https://apps.who.int/iris/handle/10665/272534.](https://apps.who.int/iris/handle/10665/272534) 8. World Health Organization. Salt reduction 2020 [Available from: [https://www.who.int/news-room/fact-sheets/detail/salt-reduction.](https://www.who.int/news-room/fact-sheets/detail/salt-reduction) 9. Health Canada. Sodium Intake of Canadians in 2017 2018 [Available from: [https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf) [nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf.](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf) 10. Flexner N, Christoforou AK, Bernstein JT, Ng AP, Yang Y, Fernandes Nilson EA, et al. Estimating Canadian sodium intakes and the health impact of meeting national and WHO recommended sodium intake levels: A macrosimulation modelling study. PLOS ONE. 2023;18(5):e0284733. 11. World Health Organization. The SHAKE Technical Package for Salt Reduction. Geneva: WHO;2016. [Available from: [https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.pdf?sequence=1.](https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.pdf?sequence=1) 12. Health Canada. Healthy Eating Strategy 2016 [Available from: [https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-](https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-strategy.html) [strategy.html.](https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-strategy.html) 13. Goverment of Canada. Voluntary sodium reduction targets for processed foods 2020- 2025 2020 [Available from: [https://www.canada.ca/en/health-canada/services/food-](https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html) [nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html.](https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html) 14. Health Canada. Sodium Reduction in Processed Foods in Canada: An Evaluation of Progress toward Voluntary Targets from 2012 to 2016 2018 [Available from: [https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-](https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-progress-report-2017/pub1-eng.pdf)

- [guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-](https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-progress-report-2017/pub1-eng.pdf)[progress-report-2017/pub1-eng.pdf.](https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-progress-report-2017/pub1-eng.pdf)
- 15. Goverment of Canada. Regulations Amending the Food and Drug Regulations (Nutrition
- Symbols, Other Labelling Provisions, Vitamin D and Hydrogenated Fats or Oils): SOR/2022-
- 168 2022 [Available from: [https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-](https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-dors168-eng.html)[dors168-eng.html.](https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-dors168-eng.html)
- 16. Scarborough P, Harrington RA, Mizdrak A, Zhou LM, Doherty A. The preventable risk
- integrated ModEl and its use to estimate the health impact of public health policy scenarios. Scientifica. 2014;2014.
- 17. Webber L, Mytton OT, Briggs AD, Woodcock J, Scarborough P, McPherson K, et al. The Brighton declaration: the value of non-communicable disease modelling in population health sciences. European journal of epidemiology. 2014;29:867-70.
- 18. Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of
- economic evaluations of population-based sodium reduction interventions. PLoS One. 2017;12(3):e0173600.
- 19. Qureshi H. The Economic Impact of Dietary Sodium Reduction in Canada. Calgary,
- Canada: University of Calgary; 2017.
- 20. Flexner N, Ng AP, Ahmed M, Khandpur N, Acton RB, Lee JJ, et al. Estimating the dietary and health impact of implementing front-of-pack nutrition labeling in Canada: A macrosimulation modeling study. Frontiers in Nutrition. 2023;10.
- 21. Flexner N, Ahmed M, Mulligan C, Bernstein JT, Christoforou AK, Lee JJ, et al. The
- estimated dietary and health impact of implementing the recently approved 'high in' front-of- package nutrition symbol in Canada: a food substitution scenario modeling study. Frontiers in Nutrition. 2023;10.
- 22. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. Ottawa: CADTH; 2017 Mar.
- 23. Dötsch-Klerk M, Bruins MJ, Detzel P, Martikainen J, Nergiz-Unal R, Roodenburg AJ, et al. Modelling health and economic impact of nutrition interventions: a systematic review.
- European Journal of Clinical Nutrition. 2022:1-14.
- 24. Cobiac LJ, Law C, Scarborough P. PRIMEtime: an epidemiological model for informing diet and obesity policy. medRxiv. 2022:2022.05. 18.22275284.
- 25. Cobiac LJ, Scarborough P, Kaur A, Rayner M. The Eatwell guide: modelling the health implications of incorporating new sugar and fibre guidelines. PLoS One. 2016;11(12).
- 26. Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity. BMC Health Serv Res. 2019;19(1):485.
- 27. Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is Doctor Referral to a Low‐
- Energy Total Diet Replacement Program Cost‐Effective for the Routine Treatment of Obesity? Obesity. 2019;27(3):391-8.
- 28. Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The
- potential health impact of restricting less-healthy food and beverage advertising on UK television
- between 05.30 and 21.00 hours: A modelling study. PLoS medicine. 2020;17(10):e1003212.
- 29. Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003
- to 2018 Population Salt Intake Reduction Program in England: A Modeling Study. Hypertension. 2021;77(4):1086-94.

- 30. Cobiac LJ, Scarborough P. Modelling the health co-benefits of sustainable diets in the
- UK, France, Finland, Italy and Sweden. European journal of clinical nutrition. 2019;73(4):624- 33.
- 31. Aminde LN, Phung HN, Phung D, Cobiac LJ, Veerman JL. Dietary salt reduction,
- prevalence of hypertension and avoidable burden of stroke in Vietnam: modelling the health and economic impacts. Frontiers in public health. 2021;9:682975.
- 32. Jackson C. Bayesian estimation of chronic disease epidemiology from incomplete data: the disbayes package 2023 [Available from:
- [https://chjackson.github.io/disbayes/articles/disbayes.html#data-required-by-the-bayesian-model.](https://chjackson.github.io/disbayes/articles/disbayes.html#data-required-by-the-bayesian-model)
- 33. World Health Organization. International Statistical Classification of Diseases and
- Related Health Problems 10th Revision 2016 [Available from:
- [https://icd.who.int/browse10/2016/en#/I20-I25.](https://icd.who.int/browse10/2016/en#/I20-I25)
- 34. Jackson C, Zapata-Diomedi B, Woodcock J. Bayesian multistate modelling of incomplete
- chronic disease burden data. Journal of the Royal Statistical Society Series A: Statistics in Society. 2023;186(1):1-19.
- 35. Health Canada. 2015 Canadian Community Health Survey Nutrition. Reference Guide
- to Understanding and Using the Data 2017 [Available from: [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)[canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)
- [community-health-survey-cchs/reference-guide-understanding-using-data-2015.html.](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)
- 36. National Academies of Sciences Engineering and Medicine. Dietary Reference Intakes
- Collection 2022 [Available from: [https://nap.nationalacademies.org/collection/57/dietary-](https://nap.nationalacademies.org/collection/57/dietary-reference-intakes)
- [reference-intakes.](https://nap.nationalacademies.org/collection/57/dietary-reference-intakes)
- 37. Bernstein JT, Christoforou AK, Flexner N, L'Abbe MR. Comparing the nutritional
- composition of foods and beverages in the Canadian Nutrient File to a large representative
- database of Canadian prepackaged foods and beverages. PLOS ONE. 2023;18(3):e0280028.
- 38. Taillie LS, Bercholz M, Popkin B, Reyes M, Colchero MA, Corvalán C. Changes in food
- purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before
- and after study. The Lancet Planetary Health. 2021;5(8):e526-e33.
- 39. Song J, Brown MK, Tan M, MacGregor GA, Webster J, Campbell NR, et al. Impact of color-coded and warning nutrition labelling schemes: A systematic review and network meta-analysis. PLoS Medicine. 2021;18(10):e1003765.
- 40. World Health Organization. Technical briefing for Appendix 3 of the Global Action Plan for Non-Communicable Diseases 2022 [Available from:
- [https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-](https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-ncd-action-plan-2013-2030)[ncd-action-plan-2013-2030.](https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-ncd-action-plan-2013-2030)
- 41. Appelhans BM, French SA, Tangney CC, Powell LM, Wang Y. To what extent do food purchases reflect shoppers' diet quality and nutrient intake? International Journal of Behavioral Nutrition and Physical Activity. 2017;14(1):1-10.
- 42. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley
- sobre composición nutricional de los alimentos y su publicidad 2017 [Available from:
- [https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%c3%b3n-Ley-](https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%c3%b3n-Ley-20606-junio-2017-PDF.pdf)
- [20606-junio-2017-PDF.pdf.](https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%c3%b3n-Ley-20606-junio-2017-PDF.pdf)
- 43. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la ley sobre composición nutricional de los alimentos y su publicidad 2018 [Available from:
- [https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementació](https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementaci)n-Ley-20606-
- febrero-18-1.pdf.

 44. Ministerio de Salud de Chile. Informe sobre evaluaciones de la Ley Nº 20.606 sobre composicion nutricional de los alimentos y su publicidad 2021 [Available from: [https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-](https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-oct2021.pdf) [oct2021.pdf.](https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-oct2021.pdf) 45. Bromberg M, Sinai T, Keinan-Boker L, Endevelt R, Frankenthal D. Current use of nutrition facts tables and attitudes towards new red and green front-of-package labels among Israeli consumers. International Journal of Food Sciences and Nutrition. 2022;73(2):230-7. 46. Shahrabani S. The impact of Israel's Front-of-Package labeling reform on consumers' behavior and intentions to change dietary habits. Israel Journal of Health Policy Research. 2021;10(1):1-11. 47. Mansfield ED, Ibanez D, Chen F, Chen E, de Grandpré E. Efficacy of "High in" Nutrient Specific Front of Package Labels—A Retail Experiment with Canadians of Varying Health Literacy Levels. Nutrients. 2020;12(10):3199. 48. Public Health Agency of Canada. Economic Burden of Illness in Canada, 2010 2018 [Available from: [https://www.canada.ca/en/public-health/services/publications/science-research-](https://www.canada.ca/en/public-health/services/publications/science-research-data/economic-burden-illness-canada-2010.html) [data/economic-burden-illness-canada-2010.html.](https://www.canada.ca/en/public-health/services/publications/science-research-data/economic-burden-illness-canada-2010.html) 49. Jones AC. Predicting the potential health and economic impact of a sugary drink tax in Canada: a modelling study: UWSpace; 2018. 50. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD 2019) Data Resources 2019 [Available from: [https://ghdx.healthdata.org/gbd-2019.](https://ghdx.healthdata.org/gbd-2019) 51. Goverment of Canada. Economic Burden of Illness in Canada custom report generator 2010 [Available from: [https://cost-illness.canada.ca/custom-personnalise/national.php.](https://cost-illness.canada.ca/custom-personnalise/national.php) 52. Krueger H, Krueger J, Koot J. Variation across Canada in the economic burden attributable to excess weight, tobacco smoking and physical inactivity. Canadian journal of Public health. 2015;106(4):e171-e7. 53. Canada S. Consumer Price Index, annual average, not seasonally adjusted. Statistics Canada: Table 18-10-0005-01 (formerly CANSIM 326-0021) 2019 [Available from: [https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501.](https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501) 54. National Cancer Institute. Usual Dietary Intakes: SAS Macros for the NCI Method 2018 [Available from: [https://epi.grants.cancer.gov/diet/usualintakes/macros.html.](https://epi.grants.cancer.gov/diet/usualintakes/macros.html) 55. Davis KA, Gonzalez A, Loukine L, Qiao C, Sadeghpour A, Vigneault M, et al. Early experience analyzing dietary intake data from the Canadian Community Health Survey— nutrition using the National Cancer Institute (NCI) method. Nutrients. 2019;11(8):1908. 56. Nilson EAF, Pearson-Stuttard J, Collins B, Guzman-Castillo M, Capewell S, O'Flaherty M, et al. Estimating the health and economic effects of the voluntary sodium reduction targets in Brazil: microsimulation analysis. BMC medicine. 2021;19(1):1-10. 57. Shangguan S, Mozaffarian D, Sy S, Lee Y, Liu J, Wilde PE, et al. Health Impact and Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary Sugar Reduction Targets in the United States: A Micro-Simulation Study. Circulation. 2021. 58. Aminde LN, Wanjau MN, Cobiac LJ, Veerman JL. Estimated Impact of Achieving the Australian National Sodium Reduction Targets on Blood Pressure, Chronic Kidney Disease Burden and Healthcare Costs: A Modelling Study. Nutrients. 2023;15(2). 59. Aminde LN, Cobiac LJ, Phung D, Phung HN, Veerman JL. Avoidable burden of stomach cancer and potential gains in healthy life years from gradual reductions in salt consumption in Vietnam, 2019–2030: A modelling study. Public Health Nutrition. 2023;26(3):586-97.

60. Aminde LN, Cobiac L, Veerman JL. Cost-effectiveness analysis of population salt

 reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling study. BMJ open. 2020;10(11):e041346.

- 61. Trieu K, Coyle DH, Afshin A, Neal B, Marklund M, Wu JH. The estimated health impact of sodium reduction through food reformulation in Australia: A modeling study. PLoS Medicine. 2021;18(10):e1003806.
- 62. Trieu K, Coyle DH, Rosewarne E, Shahid M, Yamamoto R, Nishida C, et al. Estimated
- Dietary and Health Impact of the World Health Organization's Global Sodium Benchmarks on Packaged Foods in Australia: a Modeling Study. Hypertension. 2023.
- 63. Pacheco C, Mullen KA, Coutinho T, Jaffer S, Parry M, Van Spall HGC, et al. The
- Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and
- Management of Cardiovascular Disease in Women Chapter 5: Sex- and Gender-Unique Manifestations of Cardiovascular Disease. CJC Open. 2022;4(3):243-62.
- 64. Charlton KE, Corso B, Ware L, Schutte AE, Wepener L, Minicuci N, et al. Effect of
- South Africa's interim mandatory salt reduction programme on urinary sodium excretion and
- blood pressure. Preventive medicine reports. 2021;23:101469.
- 65. World Health Organization. WHO global sodium benchmarks for different food categories. Geneva: WHO;2021. [Available from:
- [https://www.who.int/publications/i/item/9789240025097.](https://www.who.int/publications/i/item/9789240025097)
- 66. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ,
- et al. Projected effect of dietary salt reductions on future cardiovascular disease. New England
- Journal of Medicine. 2010;362(7):590-9.
- 67. Grieger JA, Johnson BJ, Wycherley TP, Golley RK. Evaluation of Simulation Models that Estimate the Effect of Dietary Strategies on Nutritional Intake: A Systematic Review. The Journal of Nutrition. 2017;147(5):908-31.
- 68. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, et al. Cost
- effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations. Bmj. 2017;356.
- 69. Kim J, Oh A, Truong H, Laszkowska M, Camargo MC, Abrams J, et al. Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model. Cancer Medicine. 2020.
- 70. Kypridemos C, Guzman-Castillo M, Hyseni L, Hickey GL, Bandosz P, Buchan I, et al.
- Estimated reductions in cardiovascular and gastric cancer disease burden through salt policies in
- England: an IMPACTNCD microsimulation study. BMJ open. 2017;7(1):e013791.
- 71. Park H-K, Lee Y, Kang B-W, Kwon K-i, Kim J-W, Kwon O-S, et al. Progress on sodium reduction in South Korea. BMJ Global Health. 2020;5(5):e002028.
- 72. Arcand J, Campbell NR. Dietary sodium reduction in Canada: more action is needed to reach the 2025 global targets. CMAJ. 2022;194(10):E387-E8.
- 73. Greer RC, Marklund M, Anderson CA, Cobb LK, Dalcin AT, Henry M, et al. Potassium-
- enriched salt substitutes as a means to lower blood pressure: benefits and risks. Hypertension. 2020;75(2):266-74.